BOSTON--(BUSINESS WIRE)--Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent 9,539,281, “Lipid-containing PSA compositions, methods of isolation and methods of use thereof,” covering the Company’s lead clinical candidate. The company, located in Boston, is developing a novel class of molecular therapeutics referred to as ZPS therapeutics, based on zwitterionic polysaccharides.
This fundamental patent expands on an extensive intellectual property portfolio which includes issued U.S. patents covering engineered production strains, nutritional supplements and use of ZPS therapeutics in specific indications. Symbiotix’ lead clinical candidate, SYMB-104, based on the first potentially therapeutic molecule to emerge from the microbiome, represents a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells with potent anti-inflammatory effects.
“We have found that zwitterionic polysaccharides are presented by MHC class II on dendritic cells, where they can stimulate the function of regulatory lymphocytes,” said Prof. Dennis Kasper, M.D., the William Ellery Channing Professor of Medicine and Professor of Microbiology and Immunobiology at Harvard Medical School, and Co-Founder of Symbiotix, “ZPS therapeutics represent a novel approach to modulating the immune system.”
“We are very pleased to see USPTO grant the very first composition-of-matter patent on a molecule that has emerged from the human microbiome,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “As one of the pioneers in the microbiome field, Symbiotix has been steadily advancing our programs and science to bring to patients first-in-class oral therapies for major immune-mediated disorders.”
About Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. At Symbiotix, we are developing a novel class of ZPS therapeutics based on molecules derived from the human microbiome. ZPS therapeutics, which have been described in over 100 scientific publications, represent the most widely tested molecules from the human microbiome and are the basis of first-in-class oral agents for the treatment of serious immune-mediated diseases such as multiple sclerosis (MS) and inflammatory bowel disease (IBD). For more information, please visit www.symbiotix-bio.com.